Загрузка...
An update: emerging drugs to treat squamous cell carcinomas of the head and neck
INTRODUCTION: Subsequent to the 2006 FDA approval of cetuximab, a variety of molecular targeting agents have been evaluated in head and neck squamous cell carcinoma (HNSCC). The treatment outcomes of recurrent and/or metastatic (R/M) HNSCC, in particular, remain dismal. The 2016 FDA approval of PD-1...
Сохранить в:
| Опубликовано в: : | Expert Opin Emerg Drugs |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6525082/ https://ncbi.nlm.nih.gov/pubmed/30376740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1543400 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|